Results 21 to 30 of about 2,846 (197)

2-Hydroxyisobutyrylation and Phosphorylation Crosstalk Guides Metastasis Prediction and Immunotherapy in Esophageal Squamous Cell Carcinoma. [PDF]

MedComm (2020)
This study deciphers the functional crosstalk between 2‐hydroxyisobutyrylation (Khib) and phosphorylation in driving esophageal squamous cell carcinoma (ESCC) metastasis. Through multi‐omics and machine learning, we developed a plasma protein signature for noninvasive detection of lymph node metastasis.
Li J, Li S, Yu X, Mu Q, Luo M, Wang Y, Liu Z, Gu C, Chen J, He W, Yang T, He Y, Pei X, Lin M, Li Z, Liu J, Zhao B, Zhang F, Liu J, Li B, Xu W.   +20 more
europepmc   +2 more sources

Overcoming Photodynamic Therapy Resistance: GSH-Responsive AIE Photosensitizer-Hydroxycamptothecin Nanoliposomes for Extrahepatic Cholangiocarcinoma. [PDF]

Adv Healthc Mater
A GSH‐responsive AIE nanoplatform (TSH NPs) with RGD‐mediated tumor targeting co‐delivers a photosensitizer (TPA) and HCPT for extrahepatic cholangiocarcinoma. The system synergistically enhances PDT and chemotherapy by suppressing HIF‐1α/VEGF‐driven hypoxic adaptation, effectively overcoming PDT resistance.
Qu Y, Peng T, Zhang Y, Cao J, Wang B, Chai C, Gao Z, Xu Y, Jin Y, Wang Y, Li Z, Liu X, Zhao T, Chen Y, Lv W, Lu D, Huang C, Ding D, Zhang J, Li M.   +19 more
europepmc   +2 more sources

Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression [PDF]

, 2014
The integrin antagonist cilengitide has been explored as an adjunct with anti-angiogenic properties to standard of care temozolomide chemoradiotherapy (TMZ/RT → TMZ) in newly diagnosed glioblastoma.
Tonn, Jörg, Ochsenbein, A, Tabatabai, G, Wick, W, Neyns, B, Clément, P M, Nikkhah, Guido, Eisele, A C, Picard, M, Stupp, R, Krex, D, Langenegger, Simon Matthias, Wick, Wolfgang, Wick, Antje, Schlegel, Uwe, Nikkhah, G, Weller, M, Eisele, G, Clément, Paul M, Ochsenbein, Adrian, Tabatabai, Ghazaleh, Eisele, Anna-Carina, Tonn, Jörg-Christian, Weller, Michael, Simon, Matthias, Stupp, Roger, Tonn, J, Clément, Paul M., Eisele, Günter, Krex, Dietmar, Schlegel, U, Clement, Paul, Neyns, Bart, Picard, Martin, Wick, A, Simon, M   +35 more
core   +3 more sources

Integrin-αvβ3 as a Therapeutic Target in Glioblastoma: Back to the Future?

Pharmaceutics, 2022
Glioblastoma (GBM), the most common primary malignant brain tumor, is associated with a dismal prognosis. Standard therapies including maximal surgical resection, radiotherapy, and temozolomide chemotherapy remain poorly efficient.
William Echavidre, Vincent Picco, Marc Faraggi, Christopher Montemagno   +3 more
doaj   +1 more source

In vitro and in vivo drug disposition of cilengitide in animals and human [PDF]

Pharmacology Research & Perspectives, 2016
AbstractCilengitide is very low permeable (1.0 nm/sec) stable cyclic pentapeptide containing an Arg‐Gly‐Asp motif responsible for selective binding to αvβ3 and αvβ5 integrins administered intravenously (i.v.). In vivo studies in the mouse and Cynomolgus monkeys showed the major component in plasma was unchanged drug (>85%).
Dolgos, Hugues, Freisleben, Achim, Wimmer, Elmar, Scheible, Holger, Krätzer, Friedrich, Yamagata, Tetsuo, Gallemann, Dieter, Fluck, Markus   +7 more
openaire   +2 more sources

Cyclic RGD Pentapeptide Cilengitide Enhances Efficacy of Gefitinib on TGF-β1-Induced Epithelial-to-Mesenchymal Transition and Invasion in Human Non-Small Cell Lung Cancer Cells

Frontiers in Pharmacology, 2021
During non-small cell lung cancer (NSCLC) progression, transforming growth factor (TGF)-β mediated epithelial-to-mesenchymal transition (EMT) is an important process leading to high mortality and poor prognosis.
Jisu Jeong, Jiyeon Kim
doaj   +1 more source

MT1‐MMP‐Activated Liposomes to Improve Tumor Blood Perfusion and Drug Delivery for Enhanced Pancreatic Cancer Therapy

Advanced Science, 2020
Promoting tumor angiogenesis effectively and specifically to resolve tumor‐associated hypoperfusion holds promise for improving pancreatic cancer therapy.
Yan Wei, Sha Song, Nianxiu Duan, Feng Wang, Yuxi Wang, Yiwei Yang, Chengyuan Peng, Junjun Li, Di Nie, Xinxin Zhang, Shiyan Guo, Chunliu Zhu, Miaorong Yu, Yong Gan   +13 more
doaj   +1 more source

Cilengitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins αvβ3 and αvβ5.

PLoS ONE, 2014
Malignant pleural mesothelioma (MPM) is an almost invariably fatal, asbestos-related malignancy arising from the mesothelial membrane lining the thoracic cavities.
Ngan Ching Cheng, Nico van Zandwijk, Glen Reid   +2 more
doaj   +1 more source

TGFβ enhances platelet-breast-cancer-cell interaction and promotes platelet aggregation. [PDF]

FEBS J
TGFβ stimulation promotes EMT in MCF7 cells, increasing their ability to bind, activate, and aggregate PLT. This effect involves the upregulation of adhesion molecules Integrin‐αv and Galectin‐3. Inhibiting Integrin‐αv or Galectin‐3, through Cilengitide and GB1103, reduces PLT adhesion to MCF7 and PLT aggregation, suggesting a mechanism linking TGFβ ...
Genitoni M, Merolle L, Razzoli A, Maurizi E, Gavioli G, Baricchi R, Marraccini C, Schiroli D.   +7 more
europepmc   +2 more sources

Cilengitide – Exceptional pseudopolymorphism of a cyclic pentapeptide

European Journal of Pharmaceutical Sciences, 2015
Cilengitide (Cil) represents a cyclic pentapeptide, cyclo-(Arg-Gly-Asp-D-Phe-N-MeVal). Existence of an anhydrate form (A1) and a tetrahydrate form Cil1(H2O)4 has been observed. Surprisingly the anhydrate form proved to be more stable in aqueous environment compared to the tetrahydrate form.
C, Saal, M, Lange, C, Kuehn, H, Untenecker, A, Jonczyk, S, Petersen, G, Scholz, V, Buback, M, Dotzauer, H, Bauer, J, Foerster, J, Schumacher, A, Metz, M, Schmidt, K, Seemann   +14 more
openaire   +2 more sources